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1 
Abstract  
Objective: We aimed to investigate the association between cardiovascular health (CVH), as 
defined by the American Heart Association, and several sleep disturbances. 
Methods: Two community-based cohorts, the Paris Prospective Study 3 (PPS3, France, n=6,441) 
and the CoLaus study (Switzerland, n=2,989) were analyzed. CVH includes 7 metrics which all 
can be classified as poor, intermediate and ideal. Global CVH score was categorized into poor 
(0-2 ideal metrics), intermediate (3-4 ideal metrics) and ideal (≥5 ideal metrics). Associations 
between global CVH and self-reported sleep disturbances [proxy of sleep-disordered breathing 
(SDB), excessive daytime sleepiness, insomnia symptoms and short/long sleep duration] and 
SDB severity measured by polysomnography (PSG) were investigated. Adjusted odds ratio 
(OR)/relative risk ratio (RRR) and 95% confidence intervals (CI) were estimated. Subjects with 
previous cardiovascular disease were excluded. 
Results: Compared to poor CVH, subjects with intermediate and ideal global CVH had lower 
odds of self-reported SDB in both cohorts (ORs up to 0.55; 95% CI 0.44-0.68 and 0.35; 95% CI 
0.22-0.53, respectively) and had lower SDB severity measured by PSG (RRR up to 0.07; 95% CI 
0.02-0.20) in CoLaus. Subjects with intermediate and ideal global CVH had lower odds of 
excessive daytime sleepiness in PPS3 (ORs 0.82; 0.72-0.95 and 0.80; 0.82-1.02, respectively). 
No consistent associations were found between CVH and sleep duration or insomnia symptoms. 
Conclusions: Higher levels of CVH are associated with lower odds of SDB and excessive 
daytime sleepiness. However, causal interpretation cannot be made and associations might be 
bidirectional. 
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Key questions 
 
What is already known about this subject? 
• Single cardiovascular risk factors are associated with sleep disturbances. 
• Although cardiovascular risk factors usually cluster, their combined effect on sleep 
disturbances remains unknown. 
 
What does this study add? 
• In two population-based cohort studies, higher cardiovascular health - a cluster of 
modifiable cardiovascular risk factors defined by the American Heart Association – was 
associated with lower odds of self-reported and objectively measured sleep disordered 
breathing (odd ratio up to 0.35; 95% confidence interval 0.22-0.53) and excessive 
daytime sleepiness (odd ratio up to 0.82; 95% confidence interval 0.72-0.95 ). 
 
How might this impact on clinical practice? 
• Given the high prevalence of sleep disordered breathing and excessive daytime sleepiness 
in the population and their adverse health consequences, promoting higher cardiovascular 
health to prevent the development of risk factors associated with sleep disordered 
breathing and excessive daytime sleepiness has the potential for important public health 
implications.  
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Introduction 
 
The prevalence of sleep disturbances such as sleep-disordered breathing (SDB, 23% in 
women and 50% in men),1 excessive daytime sleepiness (EDS, 20%),2 insomnia (17%)3 and 
short or long sleep durations (35%),4 is increasing in the population.3,5 These sleep disturbances 
have been linked to poor quality of life,6 increased risk of dementia7 and cardiovascular disease 
(CVD), and higher mortality.8–10 Therefore, identifying modifiable risk factors for sleep 
disturbances is of public health relevance. 
Single cardiovascular risk factors have been associated with several sleep 
disturbances.10,11 However, most studies considered single cardiovascular risk factors, although 
they usually cluster and have an additive effect. The association between clustered 
cardiovascular risk factors and sleep disturbances remains unclear. Furthermore, most prior 
studies focused on associations between cardiovascular risk factors and a single sleep 
disturbance, precluding to help define whether a common or a specific sleep disturbance 
prevention strategy should be recommended.  
The American Heart Association (AHA) has recently re-emphasized the concept of 
primordial prevention, i.e. the prevention of cardiovascular risk factors onset. Hence, the AHA 
developed the Life’s Simple 7, a 7-items tool including four behavioral and three biological 
metrics to define poor, intermediate and ideal cardiovascular health (CVH).12 The importance of 
CVH has been demonstrated by several population-based studies reporting substantial and 
graded risk reductions in mortality and incident CVD for subjects with intermediate and ideal 
CVH compared to those with poor CVH.13–16 Given that sleep disturbances and CVD share some 
common risk factors, we hypothesized that higher CVH would be related to lower risk of sleep 
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disturbances. Therefore, using two large contemporary community-based European studies, we 
quantified the association of CVH with several sleep disturbances.  
 
 
Methods 
 
Study population 
Details are described in the supplementary methods. 
 
The Paris Prospective Study 3 
The PPS3 (Paris, France) is a prospective observational population-based cohort study on 
novel determinants of the main phenotypes of CVD.17 Between 2008 and 2012 10,157 men and 
women aged 50-75 years were recruited in a preventive medical center. The study-protocol was 
approved by the Ethics Committee of the Cochin Hospital (Paris, France) and all volunteers 
signed an informed consent form. The standard health check-up included a complete clinical 
examination including measurement of height, weight and blood pressure, coupled with standard 
biological tests after an overnight fast. A self-administered questionnaire provided information 
related to sleep habits, lifestyle (tobacco and alcohol consumption, physical activity, diet), 
personal and family medical history and current health status. 
 
The CoLaus Study 
This is a Swiss population-based observational prospective study investigating 
determinants of cardiovascular disease.18 Between 2003 and 2006, 6,733 subjects (age range 35-
75 years) were included from a random sample of the population of Lausanne, Switzerland. The 
institutional Ethics Committee of the University of Lausanne approved the study (references 
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16/03 and 33/09) and all participants gave their signed informed consent. The first follow-up of 
the cohort (median follow-up time 5.4 years) included 5,064 subjects. Subjects underwent a 
physical examination after an overnight fasting and responded to a questionnaire covering 
demographic and medical history, health behaviors and sleep quality measures. 
 
Cardiovascular Health 
The AHA criteria were used to define the level of each metric and global CVH was 
categorized as poor, intermediate and ideal to reflect 0-2, 3-4 and 5-7 metrics at ideal.12 
Similarly, behavioral CVH (smoking, body mass index, diet and physical activity) was 
categorized as poor, intermediate and ideal to reflect 0-1, 2 and 3-4 behavioral metrics at the 
ideal level; biological CVH (hypertension, total cholesterol and fasting blood glucose) was 
categorized as poor, intermediate and ideal to reflect to 0-1, 2 and 3 metrics at the ideal level 
(supplementary methods and supplementary table 1).12 
In sensitivity analysis (see below), global CVH was examined as a continuous variable 
considering i) the number of metrics at ideal level (from 0 to 7) and ii) a global cardiovascular 
health score, calculated by assigning 0 point for each metric at poor level, 1 point for metric at 
intermediate level and 2 points for metric at ideal level (ranging from 0 to 14).12 
 
Sleep quality measures 
 
Sleep-disordered breathing 
In both cohorts, a proxy including the main risk factors for SDB was used to measure 
SDB.19 Participants reporting to snore at least 1-2 times per week (in CoLaus) or to snore 
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regularly or often (in PPS3) and being male and/or being at least 55 years old and/or having a 
BMI ≥30 kg/m2 and/or having hypertension and/or having EDS were considered to have SDB 
(supplementary table 2). 
In CoLaus, a subset of the study population underwent polysomnography.1 SDB was 
objectively measured, calculated as the average number of apnea/hypopnea per hours of sleep 
(apnea-hypopnea index, AHI), and categorized as normal (AHI 0-4), mild (AHI 5-14), moderate 
(AHI 15-29) and severe (AHI ≥30) according to the American Academy of Sleep Medicine.20 
 
Excessive daytime sleepiness 
Excessive daytime sleepiness (EDS) was assessed using the Epworth Sleepiness Scale 
(ESS) in both cohorts.21 EDS was defined by an ESS ≥11.21 
 
Sleep duration 
In both cohorts, sleep duration was extracted from the Pittsburgh Sleep Quality Index.22 
Subjects reported their average hours of sleep per night during the last month. Sleep duration was 
categorized into short (≤6 hours/night), normal (6-9 hours/night), and long (≥9 hours/night). 
 
Insomnia symptoms 
Insomnia symptoms were measured using questions from the Pittsburgh Sleep Quality 
Index. Insomnia symptoms were considered present (yes/no) when subjects reported difficulties 
initiating sleep and difficulties maintaining sleep or early morning awakening 3-4 times per 
week. 
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Confounders 
In PPS3, depression score was assessed using the 13-item Questionnaire of Depression 
second version, Abridged.23 Depressive status (yes/no) was defined by a score ≥7. In CoLaus, 
depressive status was measured with the validated 20-item Center for Epidemiologic Studies – 
Depression Scale questionnaire, and depressive status was considered for a score ≥17 for men 
and 23 for women.24 Education level was categorized as low (no graduation in PPS3, mandatory 
education or apprenticeship in CoLaus), intermediate (high school diploma) and high (university 
diploma). We categorized alcohol consumption as never/less than daily, 1-2 glasses per day and 
≥3 glasses per day. A medical doctor checked the use of medications during a face-to-face 
interview in PPS3. In CoLaus, subjects self-reported the use of prescribed and over the counter 
medications. 
 
Exclusion criteria 
Participants were excluded from the analyses if they had i) previous history of CVD; ii) 
missing data on more than one CVH metric; iii) missing data on any sleep variables or iv) 
missing data on any covariates. 
 
Statistical analyses 
Statistical analyses were performed using R version 3.3.3 for PPS3 (www.r-project.org) 
and STATA 15.1 for CoLaus (Stata Corp, College Station, TX, USA).  
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Single cohort analyses 
The association between global CVH (main exposure) and binary sleep disturbances 
(outcomes), i.e. proxy for SDB, EDS and insomnia symptoms, were examined by logistic 
regressions for each cohort and prevalence  ratios [to be considered as an odds-ratio (OR)] were 
obtained. The association between CVH and SDB measured by PSG (four categories) and sleep 
duration (three categories, with 6-9 hours/night as the reference) was quantified by multinomial 
logistic regressions and relative risk ratios (RRR) were estimated. Regression models adjusted 
for age, sex, education, living alone status, depression, use of sleep medications and alcohol 
consumption. Further, the same analyses were performed using behavioral and biological CVH 
as independent variables (secondary exposure).  
 
Pooled data cohort analyses 
Mixed effects regressions models with random effects for the cohort were used. Logistic 
mixed models were used for binary outcomes (proxy for SDB, EDS and insomnia symptoms), 
whereas linear mixed models were used for sleep duration considered here as a continuous 
outcome (the normality distribution of the model’s residuals was graphically checked). Pooled 
data analyses were adjusted for the same covariates as for the single cohort analysis. As for the 
single cohort analysis, global CVH but also behavioral and biological CVH were examined.  
 
Sensitivity analyses 
First, subjects with missing data on any CVH metrics were excluded. Second, the adapted 
CVH metric diet was measured by all available metrics in each cohort (additionally including 
sodium in PPS3 and fiber in CoLaus) and time since smoking cessation was taken into account 
Mis en forme : Anglais (États-Unis)
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for the smoking status in PPS3. Third, the association between CVH and each sleep disturbance 
was further mutually adjusted for the other three sleep disturbances. Fourth, CVH was measured 
as a continuous variable considering either the number of metrics at the ideal level (0 to 7) or the 
cardiovascular health score as defined above (ranging from 0 to 14). Next, to limit collinearity, 
BMI and hypertension were excluded from the definition of CVH and sex was not adjusted for, 
when estimating its related odds for a proxy for SDB (containing BMI, hypertension and sex in 
its definition). In this sensitivity analysis, poor, intermediate and ideal CVH corresponded to 0-2, 
3, 4-5 metrics at ideal level. Last, we assessed the relationship between global CVH and sleep 
duration measured by polysomnography in CoLaus. 
 
 
Results 
 
Study population 
From 8,583 participants in PPS3 who answered the sleep questionnaires and from the 
5,064 subjects participating in follow-up 1 in CoLaus, respectively 6,441 and 2,989 participants 
were free of previous CVD and had full data (figure 1). Out of the 2,989 subjects in CoLaus, 
1,404 had PSG data. The characteristics of excluded and included participants are compared in 
supplementary table 3. 
 
Prevalence of sleep disturbances and bivariate association with CVH 
As presented in table 1, ideal CVH was present in 9.5% (PPS3) and 11.2% (CoLaus) of 
the participants.In both cohorts, participants with ideal CVH were more frequently women, had a 
higher educational level, were more frequently living alone and drank less alcohol. Proxy for 
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SDB was present in 33% (PPS3) and 20% (CoLaus) of the participants, and decreased with an 
increasing level of global CVH in both cohorts (p-value<0.001). In CoLaus, prevalence of 
moderate/severe SDB measured by PSG was 35% and decreased with an increasing level of 
global CVH (p-value<0.001). EDS was present in 17% (PPS3) and 11% (CoLaus) of the 
participants, and decreased with increasing level of global CVH in PPS3 (p-value=0.02) but not 
in CoLaus (p-value=0.41). Insomnia symptoms were present in 14.4% (PPS3) and 7% (CoLaus) 
of the participants, and decreased with increasing level of global CVH in CoLaus (p-value=0.07) 
but not in PPS3 (p-value=0.18). There were 25% and 8% of the participants sleeping 6 hours or 
less per night in PPS3 and CoLaus respectively; and 5,1% and 1.3% sleeping 9 hours or more per 
night in each cohort. There was no clear pattern between the distribution of short/long sleep 
duration and global CVH level. 
 
Association of CVH and sleep disturbances: single cohort analysis 
 
CVH and SDB 
As presented in figure 2, in multivariable logistic regression analysis, the odds for proxy 
for SDB gradually decreased in subjects with intermediate and ideal levels of global CVH 
compared to subjects with poor CVH in both cohorts (p-value<0.001 in both cohorts). There was 
a stronger inverse gradient between higher global CVH and the severity of SDB measured by 
PSG in a subsample of CoLaus (p-value<0.001, table 2). 
These inverse associations with either the proxy for SDB (figure 2) or SDB measured by 
PSG in the subsample of CoLaus (table 2), were observed for the behavioral and biological 
CVH.  
 
 
11 
CVH and EDS 
In PPS3, subjects with intermediate and ideal global CVH had lower odds of EDS 
compared to subjects with poor CVH while no association was found in CoLaus (figure 2). 
In both cohorts, subjects with intermediate and ideal levels of behavioral CVH had lower 
odds of EDS, when compared to subjects with poor CVH, although the association with ideal 
behavioral CVH was borderline significant in CoLaus (p=0.08). Conversely, in both cohorts, 
subjects with higher biological CVH had higher odds of EDS; however these associations were 
statistically significant only for subjects with ideal compared to poor biological CVH in CoLaus. 
 
CVH, insomnia symptoms and sleep duration 
In both cohorts, no consistent associations were found between CVH and both and 
insomnia symptoms and sleep duration (supplementary table 4). 
 
Pooled analysis 
Results of the pooled analysis are reported in table 3. The odds for SDB remained 
significant, being 0.62 (95% CI 0.56 – 0.68) and 0.41 (95% CI 0.33 – 0.49) for intermediate and 
ideal global CVH when compared to poor global CVH, respectively. The odds for EDS became 
significant, being 0.87 (95% CI 0.77 – 0.99) and 0.80 (95% CI 0.65 – 0.98) for intermediate and 
ideal global CVH, respectively. As for the single cohort analysis, there was no significant 
association between intermediate and ideal global CVH and insomnia or sleep duration. 
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Sensitivity analyses 
Effect size and direction of the association between global CVH and sleep disturbances 
were consistent with those obtained in main analyses in both cohorts (supplementary table 5 
and supplementary figure 1).  
 
 
Discussion 
 
In two large European population-based studies, higher global, behavioral and biological 
CVH were consistently associated with lower odds of SDB, and higher behavioral CVH was 
related to lower odds of EDS compared to subjects with poor CVH. In addition, there was some 
evidence for an association between higher levels of CVH and lower odds for short/long sleep 
duration. Conversely, CVH was not related to insomnia symptoms. 
The distribution of ideal CVH was in the same range in PPS3 (9.5%) and CoLaus 
(11.2%). In addition, the distribution of socio-demographic characteristics across the levels of 
CVH was exactly the same in both cohorts. However, there was some difference in the 
distribution of sleep disturbances between the two studies, in particular regarding the proxy for 
SDB or short and long sleep duration, although sleep disturbances definitions have been 
harmonized as much as possible. Notwithstanding these differences, associations between CVH 
and sleep disturbances were consistent in PPS3 and CoLaus, reinforcing the robustness of the 
findings. 
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CVH and SDB 
Although several cross-sectional studies have related single cardiovascular risk factors 
with SDB,1,25 none investigated the combined association of cardiovascular risk factors as 
measured by CVH and SDB. In both PPS3 and CoLaus, the combination of several risk factors at 
intermediate or ideal compared to poor levels was associated with a reduced likelihood of having 
the proxy for SDB (up to 45% and 65% respectively). The gradual relationships between CVH 
and SDB were even stronger when the severity of SDB was objectively evaluated using PSG in 
CoLaus. Thus, the proxy for SDB is a rather conservative measure for SDB and accordingly, it 
underestimated the prevalence of SDB in CoLaus by 15% when compared to SDB measured by 
PSG. Finally, these evidences were found for both the behavioral and biological CVH. All these 
aspects emphasize the validity of the reported association between CVH and SDB. In addition, 
SDB has been shown to be a contributor to the onset of some of the CVH metrics such as 
diabetes, dyslipidemia, hypertension,10 and obesity.26 It is therefore likely that the association 
between CVH and SDB is bidirectional.  
 
CVH and EDS 
Only one small (n=635) population-based study in rural Ecuador explored the potential 
relationship between global CVH and EDS and did not find any significant association.11 
Conversely, in our study, using a much larger sample size, two independent European cohorts 
and additionally considering the behavioral and the biological components of CVH, higher 
behavioral CVH in both cohorts were significantly associated with lower odds of EDS. This 
result is in line with previous studies that associated the presence of single cardiovascular risk 
factors belonging to behavioral CVH (i.e. obesity) with EDS.27 However, the association 
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between ideal biological CVH and higher prevalence of EDS in both cohorts was unexpected 
although not confirmed in the pooled analysis, and additional studies are required to clarify this 
finding.  
 
CVH and insomnia symptoms 
The lack of consistent association between CVH and insomnia symptoms in each study is 
in line with previous studies reporting no significant relationship between single behavioral 
cardiovascular risk factors – such as obesity, physical activity or smoking – and insomnia 
symptoms.28 The present study further suggests the absence of additive effect of seven 
cardiovascular risk factors on insomnia symptoms. 
 
CVH and sleep duration 
There was little evidence for an association between CVH and sleep duration. The 
relationship was neither gradual nor consistent between the two cohorts, and sensitivity analyses 
with objectively measured sleep duration did not indicate an association either.  
 
Implications 
The lower odds of SDB and EDS associated with CVH carry important public health 
implications owing to the burden of sleep disturbances in the population and the wide range of 
sleep-related health consequences.6–10 Importantly, the lower odds for both SDB and EDS were 
primarily driven by modifiable behavioral CVH that do not require pharmacological 
interventions. The results of our sensitivity analysis on CVH score suggest that gaining one 
additional metric at ideal level is already associated with significant reduced odds of SDB and, to 
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a lesser extent, EDS. Hence, this approach might be more achievable than promoting to the 
population the attainment of an ideal global CVH to help preventing the onset of SDB and EDS. 
 
Study limitations 
First, as a cross-sectional analysis, causal interpretation cannot be made and associations 
might be bidirectional. Second, both cohorts are based on voluntary participation resulting in a 
possible overrepresentation of health aware subjects. Third, sleep disturbances, some 
cardiovascular risk factors and covariates were self-reported and thus prone to recall, 
misclassification and reporting bias. Fourth, the 7-item tool used to assess CVH assigns the same 
weights to each of the metric and further studies are required to refine the tool. Fifth, there were 
a few participants (n<30) by CVH group in some analyses of sleep disturbances, which may have 
contributed to the lack of statistical significance and wide confidence intervals. Sixth, 
declustering the Life’s Simple 7 into behavioral and biological CVH is likely to lower the 
statistical power of these sub-analyses explaining why both subscales were considered as 
secondary exposures. 
 
Conclusions 
Higher levels of CVH were associated with lower odds of SDB and EDS. In addition to 
benefit on mortality and cardiovascular disease risk, the current study suggests that higher CVH 
may have secondary benefit on highly prevalent sleep disturbances. Longitudinal and 
intervention studies are needed to support the promotion of CVH to prevent the development of 
risk factors associated with SDB and EDS. 
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Figure legends 
 
Figure 1: Selection procedure, Paris Prospective Study 3 (France) and CoLaus (Switzerland). 
 
Note: numbers are for Paris Prospective Study 3/CoLaus. 
Abbreviations: CVD: cardiovascular disease; CVH: cardiovascular health. 
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Figure 2: Association of global, behavioral and biological cardiovascular health with sleep 
disordered breathing and excessive daytime sleepiness, Paris Prospective Study 3 (France) and 
CoLaus (Switzerland). 
 
Note: multivariable analysis conducted using logistic regression; results are expressed as odds 
ratio and 95% confidence interval. 
Abbreviations: CVH: cardiovascular health, OR: odds ratio, CI: confidence interval. 
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Table 1: Characteristics of the study participants according to cardiovascular health status, 
Paris Prospective Study 3 (France, n=6,441) and CoLaus (Switzerland, n=2,989). 
 Cardiovascular health 
 
Poor Intermediate Ideal p-value 
PPS3 N=3,007 (46.7) N=2,820 (43.8) N=614 (9.5)  
Sleep complaints     
    Sleep disordered breathing (proxy) 1,206 (40.1) 780 (27.7) 117 (19.1) <0.001 
    Excessive daytime sleepiness 547 (18.2) 440 (15.6) 94 (15.3) 0.02 
    Insomnia symptoms 411 (13.7) 422 (15.0) 99 (16.1) 0.18 
    Sleep duration (hours per night)    0.27 
        ≤6 845 (28.1) 773 (27.4) 162 (26.4)  
        6-9 1,990 (66.2) 1,917 (68.0) 422 (68.2)  
        ≥9 172 (6.7) 130 (4.6) 30 (4.9)  
General characteristics     
    Male gender 2,244 (74.6) 1,600 (56.7) 271 (44.1) <0.001 
    Age (years) 59.3 ± 6.02 59.3 ± 6.21 59.2 ± 6.13 0.84 
    Education level    0.01 
        Low 851 (28.3) 704 (25.0) 152 (24.8)  
        Intermediate 566 (18.8) 517 (18.3) 103 (16.8)  
        High 1,590 (52.9) 1,599 (56.7) 359 (58.4)  
    Living alone 598 (19.9) 672 (23.8) 158 (25.7) <0.001 
    Alcohol (drinks per day)    <0.001 
        Never 469 (8.2) 314 (11.1) 98 (16.0)  
        1-2 2,229 (74.1) 2,246 (79.6) 485 (79.0)  
        ≥3 532 (17.7) 260 (19.2) 31 (5.1)  
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    Depressive status 232 (7.7) 211 (7.5) 40 (6.5) 0.59 
    Sleep medications 275 (9.1) 296 (10.5) 64 (10.4) 0.20 
CoLaus N=1,383 (46.3) N=1,272 (42.5) N=334 (11.2)  
Sleep complaints     
    Sleep disordered breathing (proxy) 392 (28.3) 176 (13.8) 27 (8.1) <0.001 
    Severity of OSA (from PSG data) 
   
 
        No 
94 (14.7) 225 (37.4) 97 (58.8) 
<0.001 
        Mild 
230 (36.1) 227 (37.8) 45 (27.3) 
 
        Moderate  
171 (26.8) 96 (16) 19 (11.5) 
 
        Severe 
143 (22.4) 53 (8.8) 4 (2.4) 
 
    Excessive daytime sleepiness 142 (10.3) 150 (11.8) 34 (10.2) 0.41 
    Insomnia symptoms 110 (8.0) 80 (6.3) 16 (4.8) 0.07 
    Sleep duration (hours per night)    0.08 
        ≤6 124 (9.0) 97 (7.6) 18 (5.4)  
        6-9 1,236 (89.4) 1,163 (91.4) 313 (93.7)  
        ≥9 23 (1.7) 12 (0.9) 3 (0.9)  
General characteristics     
    Male gender 881 (63.7) 502 (39.5) 104 (31.1) <0.001 
    Age (years) 59.0 ± 9.8 55.0 ± 9.7 50.8 ± 8.3 <0.001 
    Education    <0.001 
        Low 744 (53.8) 538 (42.3) 128 (38.3)  
        Intermediate 363 (26.2) 380 (29.9) 82 (24.6)  
        High 276 (20.0) 354 (27.8) 124 (37.1)  
    Living alone 515 (37.2) 576 (45.3) 139 (41.6) <0.001 
    Alcohol (drinks per day)    <0.001 
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        Never 226 (16.3) 290 (22.8) 100 (29.9)  
        1-2 1,107 (80.0) 964 (75.8) 233 (69.8)  
        ≥3  50 (3.6) 18 (1.4) 1 (0.3)  
    Depressive status 175 (12.7) 158 (12.4) 34 (10.2) 0.46 
    Sleep medications 186 (13.5) 140 (11.0) 36 (10.8) 0.11 
Note: numbers are N (%) or mean ± standard deviation. P-values are from Pearson chi-square 
or ANOVA where appropriate and refer to the global comparison across the 3 groups. 
Abbreviations: OSA: obstructive sleep apnea; PSG: polysomnography. 
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Table 2: Results of multinomial logistic regression between severity of sleep disordered 
breathing as measured by polysomnography and global, behavioral and biological 
cardiovascular health in CoLaus (Switzerland, N=1,404). 
  Severity of SDB (no = ref)   
 Mild Moderate Severe  
 RRR (95% CI) RRR (95% CI) RRR (95% CI)  
Global CVH     
    Poor 1 1 1  
    Intermediate 0.52 (0.38 - 0.72) 0.37 (0.25 - 0.53) 0.29 (0.19 - 0.46) 
 
    Ideal 0.27 (0.17 - 0.42) 0.20 (0.11 - 0.36) 0.07 (0.02 - 0.20) 
 
Behavioral 
CVH 
   
 
    Poor 1 1 1 
 
    Intermediate 0.59 (0.42 - 0.81) 0.43 (0.29 - 0.62) 0.38 (0.25 - 0.58) 
 
    Ideal 0.39 (0.27 - 0.57) 0.22 (0.14 - 0.37) 0.17 (0.09 - 0.31) 
 
Biological 
CVH 
   
 
    Poor 1 1 1 
 
    Intermediate 0.64 (0.46 - 0.87) 0.51 (0.34 - 0.77) 0.33 (0.19 - 0.57) 
 
    Ideal 0.27 (0.15 - 0.49) 0.30 (0.14 - 0.65) 0.13 (0.03 - 0.58) 
 
Abbreviations: SDB: sleep-disordered breathing; RRR: relative risk ratio; ref: reference 
category. Note: Models were adjusted for age, sex, education, living alone status, depression, 
use of sleep medications and alcohol consumption.
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Table 3: Results of mixed effect regressions for the pooled analysis. 
 
 SDB EDS Insomnia Sleep duration 
 OR (95% CI) OR (95% CI) OR (95% CI) Regression coefficient (95% CI) 
Global CVH     
    Poor 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
    Intermediate 0.62 (0.56 – 0.68) 0.87 (0.77 – 0.99) 0.89 (0.77 – 1.02) -0.02 (-0.03 – 0.06) 
    Ideal 0.41 (0.33 – 0.49) 0.80 (0.65 – 0.98) 0.84 (0.67 – 1.06) 0.08 (-0.01 – 0.16) 
Behavioral CVH     
    Poor 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
    Intermediate 0.66 (0.59 – 0.73) 0.76 (0.67 – 0.87) 1.01 (0.87 – 1.18) -0.003 (-0.05 – 0.05) 
    Ideal 0.41 (0.36 – 0.47) 0.72 (0.61 – 0.85) 0.93 (0.78 – 1.11) 0.06 (0.001 – 0.13) 
Biological CVH     
    Poor 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
    Intermediate 0.82 (0.72 – 0.92) 1.13 (0.98 – 1.30) 0.99 (0.84 – 1.16) 0.03 (-0.02 – 0.09) 
    Ideal 0.62 (0.48 – 0.80) 1.21 (0.93 – 1.56) 0.64 (0.44 – 0.92) -0.03 (-0.14 – 0.08) 
Abbreviations: CVH: cardiovascular health; SDB: sleep disordered breathing; EDS: excessive daytime sleepiness; OR: odd ratio; CI: confidence 
interval. 
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Note: odds ratios and regression coefficient were estimated by logistic and linear mixed effect regressions adjusted for age, sex, education, living 
alone status, depression, use of sleep medications and alcohol consumption.  
 
